▪截至2025年3月21日,正在进行中的EVER001的1b/2a期临床研究收集到了更多患者的更长期数据,其中低剂量组11位患者随访至52周,高剂量组分别有16位和12位患者完成了24周和36周治疗,并有7位患者随访至52周。▪当前数据显示,EVER001在原发性膜性肾病的患者中有效且耐受性良好。这些结果支持EVER001具有治疗以蛋白尿为特征的自身免疫性肾小球疾病的潜力。▪抗-PLA2R自身抗体...
Source Link▪截至2025年3月21日,正在进行中的EVER001的1b/2a期临床研究收集到了更多患者的更长期数据,其中低剂量组11位患者随访至52周,高剂量组分别有16位和12位患者完成了24周和36周治疗,并有7位患者随访至52周。▪当前数据显示,EVER001在原发性膜性肾病的患者中有效且耐受性良好。这些结果支持EVER001具有治疗以蛋白尿为特征的自身免疫性肾小球疾病的潜力。▪抗-PLA2R自身抗体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.